Osteoporosis in patients with rheumatoid arthritis: trends in the German National Database 2007-2017 (May, 10.1007/s00296-020-04593-6, 2020)

被引：9

作者：

Lindner, Lisa ^{[1
]}

Callhoff, Johanna ^{[1
]}

Alten, Rieke ^{[2
]}

Krause, Andreas ^{[3
]}

Ochs, Wolfgang ^{[4
]}

Zink, Angela ^{[1
,5
]}

Albrecht, Katinka ^{[1
]}

机构：

[1] German Rheumatism Res Ctr DRFZ, Epidemiol Div, Charitepl 1, D-10117 Berlin, Germany

[2] Schlosspk Klin, Internal Med Rheumatol Clin Immunol & Osteol 2, Berlin, Germany

[3] Immanuel Hosp, Rheumatol & Clin Immunol, Berlin, Germany

[4] Rheumatism Practice Bayreuth, Bayreuth, Germany

[5] Charite, Med Clin Focus Rheumatol & Clin Immunol, Berlin, Germany

来源：

RHEUMATOLOGY INTERNATIONAL | 2020年 / 40卷 / 12期

关键词：

Comorbidity; Disease activity; Glucocorticoids; Health care provision; Remission;

D O I：

10.1007/s00296-020-04725-y

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Osteoporosis is a frequent comorbidity in rheumatoid arthritis (RA). Due to the improved treatment options for RA, we expect a long-term decrease in osteoporosis as an accompanying disease. Data from the German National Database (NDB) were used to investigate whether the frequency of osteoporosis has changed in the last 10 years. From 2007 to 2017, approximately 4000 patients were documented annually with data on therapy and comorbidity. The cross-sectional data were summarised descriptively. Age, sex, disease duration, disease activity and glucocorticoids were considered as influencing factors. The Cochrane-Armitage test for trend was used to test whether the frequency of osteoporosis at the first visit changed from 2007 to 2017. Osteoporosis frequency in RA patients (mean age 63 years, 75% female) decreased from 20% in 2007 to 6% in 2017 (p < 0.001). The decrease affected women (22% to 17%) and men (14% to 8%) in all age groups and both short-term (≤ 2-year disease duration: 9% to 3%) and long-term RA patients (> 10-year disease duration: 28% to 20%). Patients with high disease activity and patients who took glucocorticoids (GC) were more often affected by osteoporosis than patients in remission or without GC. Drug prophylaxis in patients without osteoporosis increased (20% to 41% without GC, 48% to 55% with GC). Men with GC received less prophylactic treatment than women (48% vs. 57% in 2017). In this cohort, osteoporosis in patients with RA is less frequently observed compared to former years. RA-specific risk factors for osteoporosis such as disease activity and GC therapy have declined but long-term GC use is still present. Assessment of osteoporosis in RA patients should be investigated more consistently by bone density measurement. Male RA patients still need to be given greater consideration regarding osteoporosis drug prophylaxis, especially when GC therapy is needed. © 2020, The Author(s).

引用

页码：2013 / 2013

页数：1